Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Overlooked Covalent Crosslink an On/Off Switch for Proteins

Make room, disulfide crosslinks. There’s a new kind of crosslink in proteins. Instead of an S–S bridge connecting two cysteine residues, it consists of an N–O–S bridge between a lysine and a cysteine. (The “N” comes from a lysine residue’s NH2 group, the “O” i

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Make room, disulfide crosslinks. There’s a new kind of crosslink in proteins. Instead of an S–S bridge connecting two cysteine residues, it consists of an N–O–S bridge between a lysine and a cysteine. (The “N” comes from a lysine residue’s NH2 group, the “O” is an oxygen atom, and the “S” comes from a cysteine residue’s SH group.)

Like the S–S bridge, the N–O–S bridge can stabilize higher-order protein structures. Also, the formation of the N–O–S bridge appears to be chemically reversible. Accordingly, the N–O–S bridge suggests new regulatory possibilities for proteins.

The new crosslink was discovered by scientists based at Göttingen University, who anticipate that it may serve as a springboard for protein engineering as well as for drug design. Protein engineers may implement the lysine–cysteine motif into natural or designer proteins, and drug designers may find ways to target the motif with small-molecule inhibitors, antibodies, and nanobodies (or conjugates of these types of molecules).

The scientists discussed these possibilities in a paper that appeared May 5 in Nature, in an article titled, “A lysine–cysteine redox switch with an NOS bridge regulates enzyme function.” The article also describes how the scientists discovered the N–O–S bridge.

Led by Kai Tittmann, PhD, a professor of molecular enzymology at Göttingen, the scientists investigated a protein from Neisseria gonorrhoeae, a pathogen that causes gonorrhea. This disease is typically treated with antibiotics, but it threatens to become antibiotic resistant. To identify new treatments, the scientists studied the structure and mechanism of a protein that is a key player in carbon metabolism of the pathogen.

The scientists were surprised to learn that the protein can be switched on and off by oxidation and reduction (known as a redox switch). This finding led the scientists to suspect that the switching activity was due to the presence of disulfide crosslinks. When the scientists deciphered the X-ray structures of the protein in the “on” and “off” state at the DESY particle accelerator in Hamburg, Germany, they were hit by an even bigger surprise. The chemical nature of the switch was completely unknown: it is formed between a lysine and a cysteine amino acid with a bridging oxygen atom.

“X-ray structure analysis of the protein in the oxidized and reduced state reveals a loaded-spring mechanism that involves a structural relaxation upon redox activation, which is propagated from the allosteric redox switch at the protein surface to the active site in the protein interior,” the authors of the Nature article wrote. “This relaxation leads to a reconfiguration of key catalytic residues and elicits an increase in enzymatic activity of several orders of magnitude.”

Many repetitions of the experiments confirmed these results. Also, an analysis of the protein structure database further disclosed that there are many other proteins that very likely possess this switch, which apparently escaped earlier detection as the resolution of the protein structure analysis was insufficient to detect it for certain.

“I couldn’t believe my eyes,” said Tittmann of his first glimpse of the novel switch. “We thought initially that this must have formed artificially as a byproduct of the experimental process as this chemical entity was unknown.”

Tittmann and colleagues admitted that good fortune was on their side because the crystals they measured allowed the protein structure to be determined at extremely high resolution, meaning the novel switch couldn’t be missed. “The extensive screening for high-quality protein crystals has really paid off,” said Marie Wensien, a researcher in Tittmann’s laboratory and the first author of the paper. “I couldn’t be happier.”

The researchers believe the discovery of the novel protein switch will impact the life sciences in many ways. Besides enriching protein engineering and drug design, given that many proteins are redox-controlled, it could improve structure prediction.

“The spatial constraints for forming an NOS bridge are not as tight as those for a disulfide bond, as the lysine side chain is larger than that of a cysteine and thus allows for more flexibility in tethering protein chains intra- and intermolecularly,” the scientists added. “The involvement of lysine as part of the redox switch expands the regulatory tool set from that of disulfide–dithiol switches.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →